285 related articles for article (PubMed ID: 26402513)
21. Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease.
Lampela P; Tolppanen AM; Tanskanen A; Tiihonen J; Lavikainen P; Hartikainen S; Taipale H
Ann Med; 2017 May; 49(3):230-239. PubMed ID: 27786552
[TBL] [Abstract][Full Text] [Related]
22. Medical interventions suppressed progression of advanced Alzheimer's disease more than mild Alzheimer's disease.
Honjo Y; Ide K; Takechi H
Geriatr Gerontol Int; 2020 Apr; 20(4):324-328. PubMed ID: 32037700
[TBL] [Abstract][Full Text] [Related]
23. Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy.
Modrego PJ; Fayed N; Errea JM; Rios C; Pina MA; Sarasa M
Eur J Neurol; 2010 Mar; 17(3):405-12. PubMed ID: 19874395
[TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil or galantamine.
López-Pousa S; Olmo JG; Franch JV; Estrada AT; Cors OS; Nierga IP; Gelada-Batlle E
Age Ageing; 2006 Jul; 35(4):365-71. PubMed ID: 16788079
[TBL] [Abstract][Full Text] [Related]
25. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
Wattmo C; Minthon L; Wallin ÅK
Alzheimers Res Ther; 2016 Feb; 8():7. PubMed ID: 26883213
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: a critically appraised topic.
Riordan KC; Hoffman Snyder CR; Wellik KE; Caselli RJ; Wingerchuk DM; Demaerschalk BM
Neurologist; 2011 Mar; 17(2):121-3. PubMed ID: 21364371
[TBL] [Abstract][Full Text] [Related]
27. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
[TBL] [Abstract][Full Text] [Related]
28. The effects of combine treatment of memantine and donepezil on Alzheimer's disease patients and its relationship with cerebral blood flow in the prefrontal area.
Araki T; Wake R; Miyaoka T; Kawakami K; Nagahama M; Furuya M; Limoa E; Liaury K; Hashioka S; Murotani K; Horiguchi J
Int J Geriatr Psychiatry; 2014 Sep; 29(9):881-9. PubMed ID: 24436135
[TBL] [Abstract][Full Text] [Related]
29. Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study.
Scharre DW; Vekeman F; Lefebvre P; Mody-Patel N; Kahler KH; Duh MS
Drugs Aging; 2010 Nov; 27(11):903-13. PubMed ID: 20964464
[TBL] [Abstract][Full Text] [Related]
30. Effective pharmacological management of Alzheimer's disease.
Atri A
Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
[TBL] [Abstract][Full Text] [Related]
31. Drugs for cognitive loss and dementia.
Treat Guidel Med Lett; 2013 Oct; 11(134):95-100; quiz 1 p following p100.. PubMed ID: 24081314
[TBL] [Abstract][Full Text] [Related]
32. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
Feldman HH; Schmitt FA; Olin JT;
Alzheimer Dis Assoc Disord; 2006; 20(4):263-8. PubMed ID: 17132971
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.
Sakka P; Tsolaki M; Hort J; Hager K; Soininen H; López Pousa S; Li C; Schwam E
Curr Med Res Opin; 2007 Dec; 23(12):3153-65. PubMed ID: 17988434
[TBL] [Abstract][Full Text] [Related]
34. Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model.
Van Dam D; Abramowski D; Staufenbiel M; De Deyn PP
Psychopharmacology (Berl); 2005 Jun; 180(1):177-90. PubMed ID: 15654502
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
[TBL] [Abstract][Full Text] [Related]
36. Two galantamine titration regimens in patients switched from donepezil.
Engedal K; Davis B; Richarz U; Han J; Schäuble B; Andreasen N
Acta Neurol Scand; 2012 Jul; 126(1):37-44. PubMed ID: 21992111
[TBL] [Abstract][Full Text] [Related]
37. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.
Pouryamout L; Dams J; Wasem J; Dodel R; Neumann A
Drugs; 2012 Apr; 72(6):789-802. PubMed ID: 22480339
[TBL] [Abstract][Full Text] [Related]
38. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
Prasher VP
Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
[TBL] [Abstract][Full Text] [Related]
39. Prescribing of drugs for Alzheimer's disease: a South African database analysis.
Truter I
Int Psychogeriatr; 2010 Mar; 22(2):264-9. PubMed ID: 20067653
[TBL] [Abstract][Full Text] [Related]
40. [Current approaches to optimize treatment of dementia and Alzheimer's disease].
Kolykhalov IV
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(6):87-92. PubMed ID: 28635795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
